What Researchers Did
Researchers conducted a prospective study with 123 patients suffering from acute severe carbon monoxide poisoning, randomly assigning them to either a control group receiving standard medical treatment including hyperbaric oxygen, or an observation group that received ulinastatin in addition to standard care.
What They Found
The observation group, treated with ulinastatin, showed significantly lower average levels of heart injury markers (BNP, cTNI, CK-MB, CK) at 3, 7, and 14 days compared to the control group (P<0.05). Furthermore, the case fatality rate within 14 days was lower in the observation group at 1.2% compared to 3.3% in the control group.
What This Means for Canadian Patients
This study suggests that adding ulinastatin to standard treatments, such as hyperbaric oxygen therapy (HBOT), could help reduce heart damage and improve survival rates for Canadian patients with severe carbon monoxide poisoning. It offers a potential adjunctive therapy to enhance cardiac protection and overall prognosis in this critical condition.
Canadian Relevance
This study was not conducted in Canada and does not involve Canadian authors. However, it covers a Health Canada-recognized indication (carbon monoxide poisoning) for hyperbaric oxygen therapy.
Study Limitations
This study was conducted at a single hospital and had a relatively short follow-up period of 14 days for mortality outcomes.